For research use only
| Cat No. | ABC-TC0112 |
| Product Type | Human Lung Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Lung Adenocarinoma |
| Product Code | CaLu-6; CALU-6; Calu.6; Calu 6; Calu6; CALU6; CaLu-06 |
From anaplastic lung carcinoma, Calu-6 carries KRAS Q61K mutation, p53-null, S100A6-sensitive, ideal for DNA repair, renin regulation, and tumor modeling.
Calu-6 is a human lung adenocarcinoma cell line derived from pleural effusion of a 61-year-old female with lung adenocarcinoma (originally diagnosed as anaplastic carcinoma). These epithelial-like, adherent cells form monolayers in culture. Karyotypically hypotriploid (modal chromosomes: 59, −Y) and harboring 14 marker chromosomes, Calu-6 carries a heterozygous KRAS p. Gln61Lys mutation, lacks p53 expression, and displays FA-BRCA pathway defects, supporting use in oncogenesis and DNA repair research. Tumorigenic in nude mice, these cells model poorly differentiated carcinomas and are widely used to investigate tumor suppressors and therapies. Exogenous S100A6 overexpression inhibits proliferation/migration while inducing apoptosis, and endogenous renin mRNA expression (upregulated by cAMP) enables renin regulation studies.
| Product Code | CaLu-6; CALU-6; Calu.6; Calu 6; Calu6; CALU6; CaLu-06 |
| Species | Human |
| Cat.No | ABC-TC0112 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Lung Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
The Calu-6 cell line is utilized as a model to study tumor suppressor pathways (e.g., p53/FA-BRCA) and pathways for potential therapies. It has been instrumental in studying the antiproliferative mechanism of apoptosis and understanding the molecular mechanisms of cytotoxic drugs used in lung cancer treatment. Additionally, Calu-6 contributes to the development of novel agents that target specific intracellular pathways associated with cancer cell properties, aiding the ongoing efforts in developing effective treatments primarily for KRAS-driven cancers (e.g., lung/pancreatic).
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
